Marshall Wace LLP raised its position in Tenet Healthcare Co. (NYSE:THC – Get Rating) by 338.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 138,955 shares of the company’s stock after purchasing an additional 107,265 shares during the period. Marshall Wace LLP owned approximately 0.13% of Tenet Healthcare worth $7,167,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Tenet Healthcare by 0.7% in the first quarter. Vanguard Group Inc. now owns 10,932,708 shares of the company’s stock valued at $939,775,000 after purchasing an additional 77,543 shares in the last quarter. FMR LLC increased its stake in Tenet Healthcare by 30.6% in the second quarter. FMR LLC now owns 6,940,816 shares of the company’s stock valued at $364,810,000 after purchasing an additional 1,625,431 shares in the last quarter. State Street Corp increased its stake in Tenet Healthcare by 2.4% in the first quarter. State Street Corp now owns 3,377,944 shares of the company’s stock valued at $290,368,000 after purchasing an additional 78,687 shares in the last quarter. Samlyn Capital LLC increased its position in shares of Tenet Healthcare by 96.2% during the third quarter. Samlyn Capital LLC now owns 2,811,314 shares of the company’s stock worth $145,007,000 after acquiring an additional 1,378,162 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Tenet Healthcare by 23.6% during the first quarter. Goldman Sachs Group Inc. now owns 2,180,627 shares of the company’s stock worth $187,446,000 after acquiring an additional 415,945 shares in the last quarter. Institutional investors own 98.14% of the company’s stock.
Tenet Healthcare Stock Performance
NYSE THC opened at $52.58 on Friday. The firm has a 50-day moving average of $55.45 and a 200-day moving average of $51.60. The company has a debt-to-equity ratio of 6.07, a quick ratio of 1.25 and a current ratio of 1.34. The stock has a market cap of $5.38 billion, a PE ratio of 14.17, a P/E/G ratio of 2.86 and a beta of 2.14. Tenet Healthcare Co. has a 52-week low of $36.69 and a 52-week high of $92.65.
Insider Transactions at Tenet Healthcare
In other Tenet Healthcare news, EVP Thomas W. Arnst sold 825 shares of Tenet Healthcare stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $61.00, for a total value of $50,325.00. Following the completion of the sale, the executive vice president now owns 22,778 shares in the company, valued at approximately $1,389,458. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Tenet Healthcare news, Director Tammy Romo sold 7,000 shares of Tenet Healthcare stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $60.95, for a total value of $426,650.00. Following the completion of the sale, the director now owns 57,598 shares in the company, valued at approximately $3,510,598.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Thomas W. Arnst sold 825 shares of Tenet Healthcare stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $61.00, for a total transaction of $50,325.00. Following the completion of the sale, the executive vice president now owns 22,778 shares of the company’s stock, valued at approximately $1,389,458. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on THC shares. Mizuho increased their price objective on shares of Tenet Healthcare from $60.00 to $78.00 and gave the stock a “buy” rating in a research report on Friday, February 17th. Royal Bank of Canada increased their price objective on shares of Tenet Healthcare from $69.00 to $73.00 and gave the stock an “outperform” rating in a research report on Friday, February 10th. Loop Capital raised their target price on shares of Tenet Healthcare from $40.00 to $45.00 in a research report on Tuesday, December 6th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Tenet Healthcare from $48.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, February 10th. Finally, Wells Fargo & Company raised their target price on shares of Tenet Healthcare from $59.00 to $68.00 and gave the company an “overweight” rating in a research report on Friday, February 17th. One analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $69.47.
About Tenet Healthcare
Tenet Healthcare Corp. engages in the provision of healthcare services. It operates through the following segments: Hospital Operations and Other, Ambulatory Care, and Conifer. The Hospital Operations and Other segment is composed of acute care hospitals, ancillary outpatient facilities, urgent care centers, micro hospitals and physician practices.
Featured Articles
- Get a free copy of the StockNews.com research report on Tenet Healthcare (THC)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Tenet Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenet Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
